Lung Cancer Cachexia

  • Rowan T. Chlebowski
  • David Heber
  • Jerome B. Block
Part of the Cancer Treatment and Research book series (CTAR, volume 11)


Weight loss in patients with advanced lung carcinoma has been recognized clinically for many years. However, only recently has the prognostic significance of weight loss in patients with this disease been identified. In one report by Costa and co-workers [1] the incidence, timing, and severity of weight loss in a total of 479 patients with lung cancer was related to patient survival. At their initial clinical presentation, 47% of lung cancer patients had lost at least 5% of their usual body weight. The survival of these patients was significantly less than that of patients not experiencing weight loss, even when corrected for factors such as age, sex, extent of disease, cell type and performance score [1]. An analysis of 1,026 patients from the Eastern Cooperative Oncology Group revealed evidence of weight loss during the previous 6 months in 57% of small cell and 61% of non-small cell lung cancer patients [2]. In both categories of lung cancer, median survival was significantly decreased for patients experiencing antecedent weight loss prior to protocol chemotherapy: 34 weeks vs 27 weeks in small cell; 20 weeks vs 14 weeks in non-small cell. The influence of weight loss on survival in these large reports exceeds the current influence of chemotherapy on survival in non-small cell disease. Thus, weight loss at the time of clinical presentation is an important, independent factor prognostic of survival in patients with lung cancer.


Lung Cancer Patient Total Parenteral Nutrition Cancer Cachexia Taste Sensation Glucose Turnover 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Costa G, Lane WW, Vincent RG, Siebold J A, Aragon M, Bewley PT: Weight loss and cachexia in lung cancer. Nutrition and Cancer 2: 98–103, 1981.CrossRefGoogle Scholar
  2. 2.
    DeWys WD, Begg C, Lavin PT, et al: Prognostic effect of weight loss prior to chemotherapy in cancer patients. Am J Med 69: 491–498, 1980.PubMedCrossRefGoogle Scholar
  3. 3.
    Bernstein IL: Physiological and psychological mechanisms of cancer anorexia. Cancer Res (suppl) 42: 715s–720s, 1982.Google Scholar
  4. 4.
    DeWys WD: Anorexia as a general effect of cancer. Cancer 43: 2013–2019, 1979.PubMedCrossRefGoogle Scholar
  5. 5.
    Theologides A: Anorexia in cancer: another speculation on its pathogenesis: Nutrition and Cancer 2: 133–135, 1981.PubMedCrossRefGoogle Scholar
  6. 6.
    DeWys WD, Walters K: Abnormalities of taste sensation in cancer patients. Cancer 36: 1888–1896, 1975.PubMedCrossRefGoogle Scholar
  7. 7.
    DeWys WD: Taste abnormalities and caloric intake in cancer patients: a review. J Human Nutr 32: 447–453, 1978.Google Scholar
  8. 8.
    Carson J AS, Gormican A: Taste acquity and food attitudes of selected patients with cancer. J Am Diet Assoc 70: 361–364, 1977.PubMedGoogle Scholar
  9. 9.
    Williams LR, Cohen MH: Altered taste thresholds in lung cancer. Am J Clin Nutr 31: 122–125, 1978.PubMedGoogle Scholar
  10. 10.
    Hall JC, Staniland JR, Giles I: Altered taste thresholds in gastrointestinal cancer. Clinical Oncology 6: 137–142, 1980.PubMedGoogle Scholar
  11. 11.
    Conger AD, Wells MA: Radiation and aging effects on taste structure and function. Radiation Res 37: 31–38, 1969.PubMedCrossRefGoogle Scholar
  12. 12.
    Kaplan AR: The effect of cigarette smoking on malnutrition and digestion. Gastroenterology 61: 208, 1963.Google Scholar
  13. 13.
    Henkin R : Taste loss in aging. In: The Biomedical Role of Trace Elements in Aging. Davis HJ, Neithmeimer R, St Petersburg R (eds). Eckerd College Gerontology Center, 1976, pp 221–236.Google Scholar
  14. 14.
    Barai B, DeWys W: Assay for presence of anorectic substance in mine of cancer patients. Proc Amer Assoc Can Res 21: 378, 1980.Google Scholar
  15. 15.
    Pareira MD, Conrad EJ, Hicks W, Elman R: Clinical response and changes in nitrogen balance, body weight, plasma proteins, and hemoglobin following tube feeding in cancer cachexia. Cancer 8: 803–808, 1955.PubMedCrossRefGoogle Scholar
  16. 16.
    Terepka AR, Waterhouse C: Metabolic observations during forced feeding of patients with cancer. Am J Med 20: 225–238, 1956.PubMedCrossRefGoogle Scholar
  17. 17.
    Rickard KA, Kirsey A, Baehner RL, et al.: Nutritional management of children with advanced cancer: effectiveness of enteral and parenteral nutrition. Fed Proc 38:865, 1979.Google Scholar
  18. 18.
    Young VR: Energy metabolism and requirements in the cancer patient. Cancer Res 37: 2336–2341, 1977.PubMedGoogle Scholar
  19. 19.
    Silver S, Poroto P, Crohn EB: Hypermetabolic states without hyperthyroidism. Arch Intern Med 85: 479–482, 1950.Google Scholar
  20. 20.
    Waterhouse C: How tumors affect host metabolism. Ann NY Acad Sci 230: 86–93, 1974.PubMedCrossRefGoogle Scholar
  21. 21.
    Waterhouse CL, Fenninger LD, Kentmann EH: Nitrogen exchange and caloric expenditure in patients with malignant neoplasm. Cancer 4: 500–514, 1951.PubMedCrossRefGoogle Scholar
  22. 22.
    Watkin DM: Nitrogen balance as affected by neoplastic disease and its therapy. Am J Clin Nutr 9: 446–460, 1961.PubMedGoogle Scholar
  23. 23.
    Warnold I, Lundholm K, Schersten T: Energy balance and body composition in cancer patients. Cancer Res 38: 1801–1807, 1978.PubMedGoogle Scholar
  24. 24.
    Bozzetti F, Pagnoni AM, Vecchio MD: Excessive caloric expenditures as a cause of malnutrition in patients with cancer. Surg Gyn Obstet 150: 229–234, 1980.Google Scholar
  25. 25.
    Watson WS, Sammon AM: Body composition in cachexia resulting from malignant and non-malignant disease. Cancer 46: 2041–2046, 1981.CrossRefGoogle Scholar
  26. 26.
    Cohn SH, Gartenhaus W, Sawitsky A, Rai K, Zanzi I, Vaswani A, Ellis KJ, Vartsky D: Compartmental body composition of cancer patients by measurement of total body nitrogen, potassium, and water. Metabolism 30: 22–229, 1981.CrossRefGoogle Scholar
  27. 27.
    Nixon DW, Heymsfield SB, Cohen AE, Kutner MH, Ansley J, Lawson DH, Rudman D: Protein-calorie undernutrition in hospitalized cancer patients. Am J Med 68: 683–690, 1980.PubMedCrossRefGoogle Scholar
  28. 28.
    Rohdenberg GL, Bernhard A, Krehbiel O: Sugar tolerance in cancer. JAMA 72: 1528–1529, 1919.Google Scholar
  29. 29.
    Marks PA, Bishop JS: The glucose metabolism of patients with malignant disease and of normal subjects as studied by means of an intravenous glucose tolerance test. J Clin Invest 36: 254–264, 1957.PubMedCrossRefGoogle Scholar
  30. 30.
    Chlebowski RT, Heber D, Block JB: Serial assessment of glucose metabolism in patients with cancer cachexia. Clin Res 30: 69A, 1982.Google Scholar
  31. 31.
    Bishop JS, Marks PA: Studies on carbohydrate metabolism in patients with neoplastic disease II. Response to insulin administration. J Clin Invest 38: 688–672, 1959.CrossRefGoogle Scholar
  32. 32.
    Schein P, Kisner D, Haller D, Blecher M, Hamosh M: Cachexia of malignancy: potential role of insulin in nutritional management. Cancer 43: 2070–2076, 1979.PubMedCrossRefGoogle Scholar
  33. 33.
    Gold J: Cancer cachexia and gluconeogenesis. Ann NY Acad Sci 230: 103–110, 1975.CrossRefGoogle Scholar
  34. 34.
    Costa G: Cachexia, the metabolic component of neoplastic disease Cancer Res 37: 2327–2335, 1977.Google Scholar
  35. 35.
    Block JB: Lactic acidosis in malignancy and observation on its possible pathogenesis. Ann NY Acad Sci 230: 94–102, 1974.PubMedCrossRefGoogle Scholar
  36. 36.
    Field M, Block JB, Leven R, Rail DP: The significance of elevations of blood lactate in patients with neoplastic and other proliferative disorders. Am J Med 40: 528–547, 1966.CrossRefGoogle Scholar
  37. 37.
    Clark EF, Lewis AM, Waterhouse C: Peripheral amino acid levels in patients with cancer. Cancer 42: 2909–2913, 1978.CrossRefGoogle Scholar
  38. 38.
    Holroyde CP, Gabuzda TG, Putnam RC, Paul P, Reinchard GA: Altered metabolism in metastatic carcinoma. Cancer Res 35: 3710–3714, 1978.Google Scholar
  39. 39.
    Reichard GA, Joury NF, Hochella NJ, et al.: Quantitative estimation of the Cori cycle in the human. J Biol Chem 238:495–501, 1963.Google Scholar
  40. 40.
    Burt ME, Gorschboth CM, Brennan MF: A controlled, prospective, randomized trial evaluating metabolic effects of enteral and parenteral nutrition in the cancer patient. Cancer 49: 1092–1105, 1982.PubMedCrossRefGoogle Scholar
  41. 41.
    Stein TP: Cachexia, gluconeogenesis and progressive weight loss in cancer patients. J Theor Biol 73: 51–59, 1978.PubMedCrossRefGoogle Scholar
  42. 42.
    Theologides A: Cancer cachexia. Cancer 43: 2004–2012, 1979.PubMedCrossRefGoogle Scholar
  43. 43.
    Fenninger LD, Mider GB: Energy and nitrogen metabolism in cancer. Adv Cancer Res 2: 229, 1954.PubMedCrossRefGoogle Scholar
  44. 44.
    Lundholm K, Bylund AC, Holm J, Scherstein T: Skeletal muscle metabolism in patients with malignant tumor. Eur J Cancer 12: 465–471, 1976.PubMedGoogle Scholar
  45. 45.
    Lundholm K, Holm G, Schersten T: Insulin resistance in patients with cancer. Cancer Res 38: 4665–4670, 1978.PubMedGoogle Scholar
  46. 46.
    Levin L, Gevers W: Metabolic alterations in cancer. South African Medical Journal 59: 553–555, 1981.PubMedGoogle Scholar
  47. 47.
    Norton JA, Stein TP, Brennan MF: Whole body protein synthesis and turnover in normal man and malnourished patients with and without known cancer. Ann Surg 194: 123–128, 1981.PubMedCrossRefGoogle Scholar
  48. 48.
    Axelrod L, Costa G: The contribution of fat loss to weight loss in cancer. Nutr Cancer 2: 81–83, 1980.CrossRefGoogle Scholar
  49. 49.
    Waterhouse C, Kemperman J: Carbohydrate metabolism in subjects with cancer. Cancer Res 31: 1273–1278, 1971.PubMedGoogle Scholar
  50. 50.
    Wilson JD, Griffin JE: The use and misuse of androgens. Metabolism 29: 1278–1294, 1980.PubMedCrossRefGoogle Scholar
  51. 51.
    Chlebowski RT, Heber D: Hypogonadism in male patients with metastatic cancer prior to chemotherapy. Cancer Res 42: 2495–2498, 1982.PubMedGoogle Scholar
  52. 52.
    Heber D, Chlebowski RT, Ishibashi DE, Herrold JN, Block JB: Metabolic abnormalities in lung cancer patients. Cancer Res 42: 4815–4819, 1982.PubMedGoogle Scholar
  53. 53.
    Ray PD, Hanson RL, Lardy HA: Inhibition by hydrazine of gluconeogenesis in the rat. J Biol Chem 245: 690–696, 1970.PubMedGoogle Scholar
  54. 54.
    Fortney SR, Clark DA, Stein EJ: Inhibition of gluconeogenesis by hydrazine administration in rats. J Pharmacol Exp Ther 156: 277–284, 1972.Google Scholar
  55. 55.
    Gold J: Inhibition by hydrazine sulfate and various hydrazines of in vivo growth of Walker 256 intramuscular carcinoma, B-16 melanoma, Murphy-Stern lymphosarcoma and L-1210 leukemia. Oncology 27: 69–80, 1973.PubMedCrossRefGoogle Scholar
  56. 56.
    Gold J: Use of hydrazine sulfate in terminal and preterminal cancer patients. Oncology 32: 1–10, 1975.PubMedCrossRefGoogle Scholar
  57. 57.
    Gershanovich ML, Danova LA, Ivin BA, Filov VA: Results of clinical study of antitumor action of hydrazine sulfate. Nutr and Cancer 3: 7–12, 1982.CrossRefGoogle Scholar
  58. 58.
    Spremulli E, Wampler GL, Regelson W: Clinical study of hydrazine sulfate in advanced cancer patients. Cancer Chemother Pharm 3: 121–124, 1979.CrossRefGoogle Scholar
  59. 59.
    Lerner HJ, Regelson W: Clinical trial of hydrazine sulfate in solid tumors. Cancer Treat Rep 60: 959–960, 1976.PubMedGoogle Scholar
  60. 60.
    Heymsfield SB, Bethel RA, Ansley JD, et al.: Enteral hyperalimentation: an alternative to central venous hyperalimentation. Ann Int Med 90: 63–72, 1979.PubMedGoogle Scholar
  61. 61.
    Kaminski MU: Enteral hyperalimentation. Surg Gyn Obst 143: 12–21, 1976.PubMedGoogle Scholar
  62. 62.
    Loh KK, Inasmasu MS, Melish S, et al.: Enteral hyperalimentation in the treatment of malnourished cancer patients. Proc Am Assoc Cancer Res 20:301, 1979.Google Scholar
  63. 63.
    Block JB, Chlebowski RT, Herrold J: Continuous enteric alimentation with a blenderized formular in cancer cachexia. Clin Onco 7: 93–98, 1981.Google Scholar
  64. 64.
    Nixon DW, Lawson DH, Dutner M, et al.: Hyperalimentation of the cancer patients with protein-calorie undernutrition. Cancer Res 41:2038–2045, 1981.PubMedGoogle Scholar
  65. 65.
    Nixon DW: Hyperalimentation in the undernourished cancer patient. Cancer Res (suppl) 42: 727s–728s, 1982.PubMedGoogle Scholar
  66. 66.
    Lipschitz DA, Mitchell CO: Enteral hyperalimentation and hematopoietic toxicity caused by chemotherapy of small cell lung cancer. JPEN 4: 593, 1980.Google Scholar
  67. 67.
    Copeland EM, Macfayder BV, Dudrick SJ: Effect of hyperalimentation on established delayed hypersensitivity in the cancer patients. Ann Surg 184: 60–64, 1976.PubMedCrossRefGoogle Scholar
  68. 68.
    Hickman RD, Buckner CD, Clift RA, et al.: A modified right atrial cathether for access to the venous system in marrow transplant recipients. Surg Gynecol Obstet 148:872–875, 1979.Google Scholar
  69. 69.
    Broviac JW, Cole JJ, Scribner BH: A silicone rubber atrial catheter for prolonged parenteral alimentation. Surg Gynecol Obstet 136: 602–607, 1974.Google Scholar
  70. 70.
    Brennan MF. Total parenteral nutrition in the cancer patient. N Engl J Med 305: 375–382, 1981.PubMedCrossRefGoogle Scholar
  71. 71.
    Brennan MF, Copeland EM: Panel report on nutritional assessment and prechemotherapy hyperalimentation in adenocarcinoma of the lung. Proc Am Assoc Cancer Res 20: 412, 1979.Google Scholar
  72. 72.
    Levine AS, Brennan MF, Ramu A, et al.: Controlled clinical trials of nutritional intervention as an adjacent to chemotherapy with a comment on nutrition and drug resistance. Cancer Res (suppl) 42:774s–781s, 1982.Google Scholar
  73. 73.
    Jordan WM, Valdivieso M, Freeman M, et al.: Importance of nutritional assessment and prechemotherapy hyperalimentation in adenocarcinoma of the lung. Proc Am Assoc Cancer Res 20:412, 1979.Google Scholar
  74. 74.
    Jordan WM, Valdivieso M, Frankmann C, Gillespie M, Issell BF, Bodey GP, Freireich EJ: Treatment of advanced adenocarcinoma of the lung with ftorafur, doxorubicin, cyclophosphamide, and cis-platin (FACP) and intensive IV hyperalimentation. Cancer Treat Rep 65: 197–206, 1981.PubMedGoogle Scholar
  75. 75.
    Valdivieso M, Bodey G, Barkley T, Benjamin R, Mountain C: Randomized evaluation of intravenous hyperalimentation during intensive chemotherapy for small cell lung cancer. Proc Am Assoc Clin Oncol 21:C-560, 1980.Google Scholar
  76. 76.
    Issell BF, Valdivieso M, Zaren HA, et al.: Protection against chemotherapy toxicity by IV hyperalimentation. Cancer Treat Rep 62:1139–1143, 1978.PubMedGoogle Scholar
  77. 77.
    Serrou B, Cupissol D, Favier F, Michel FB: Opposite results in two randomized trials evaluating the adjunct value of peripheral intravenous nutrition in lung cancer patients. In: Adjuvant Therapy of Cancer III. Salmon SE, Jones SE (eds). New York: Grune and Stratton, 1981, pp 255–261.Google Scholar
  78. 78.
    Muller JM, Dienst C, Brenner U, Pichlmaier H: Preoperative parenteral feeding in patients with gastrointestinal carcinoma. Lancet 1: 68–71, 1982.PubMedCrossRefGoogle Scholar
  79. 79.
    Lanzotti V, Copeland E, Bhuchar V, Wesley M, Corriere J, Dudrick S: A randomized trial of total parenteral nutrition (TPN) with chemotherapy for non-oat cell lung cancer. Proc Am Assoc Can Res 21: 377, 1980.Google Scholar
  80. 80.
    Lanzotti VJ, Thomas DR, Boyle LD, et al.: Survival with inoperable lung cancer: an integration of prognostic variables based on simple clinical criteria. Cancer 33:303–313, 1977.CrossRefGoogle Scholar
  81. 81.
    DeWys W: Pathophysiology of cancer cachexia: current understanding and areas for future research. Cancer Res (suppl) 42: 721s–726s, 1982.Google Scholar

Copyright information

© Martinus Nijhoff Publishers, Boston 1983

Authors and Affiliations

  • Rowan T. Chlebowski
  • David Heber
  • Jerome B. Block

There are no affiliations available

Personalised recommendations